DESCRIPTION OF THE PREFERRED EMBODIMENTS

Page 17, replace the paragraph beginning at line 14 with the following paragraph:

Any kind of carbon source and nitrogen source can be used in the medium as long as they can be utilized by the transformant of the present invention. As the anabolizable carbon source, for example, various carbohydrates, such as sucrose, glucose, starch, sucrose, glycerol, fructose, maltose, mannitol, xylose, galactose, ribose, dextrin, animal and plant oils and the like, or hydrolysates thereof, can be used. The preferable concentration generally is from 0.1% to 5% of the medium.

Page 31, replace the paragraph beginning at line 19 with the following paragraph:

The PCR product thus obtained was labeled using an ECL Direct System (Amersham Pharmacia Biotech). The phage plaque prepared as described above was transferred to a Hybond N+ nylon transfer membrane (Amersham Pharmacia Biotech), and after alkaline denaturation, the membrane was washed with 5xSSC (SSC: 15 mM trisodium citrate, 150 mM sodium chloride) and dried to immobilize the DNA. According to the kit protocol, prehybridization (42°C) was carried out for 1 hour, after which the above-mentioned labeled probe was added, and hybridization was carried out at 42°C for 16 hours. The nylon membrane was washed according to the kit protocol described above. The washed nylon membrane was immersed for one minute in a detection solution and then photosensitized on a medical X-ray film (Fuji Photo Film Co., Ltd.) to obtain one positive clone. Southern blot analysis of this clone showed that a HindIII fragment of at least 6 kb was identical with the restriction enzyme fragment long of the genomic DNA. Figure 9 shows the restriction map of this HindIII fragment. The

HindIII fragment was subcloned into pUC119 to obtain pRQHin/119 for use of the following experiment.

Page 32, replace the paragraph beginning at line 29 with the following paragraph:

Next, pPF260-A was double-digested with restriction enzymes PstI and BamHI to prepare a DNA fragment of approximately 1.7 kbp. This fragment was subcloned into PstI and BamHI sites of pUC119 to obtain plasmid pUC119-A. Treatment for site-directed mutagenesis was carried out with pUC119-A as a template DNA and the oligonucleotide of SEQ ID NO: 21 as a primer using a Muta-Gene in vitro Mutagenesis Kit (Bio-Rad) to obtain plasmid pUC119-A1.

replace the paragraph beginning at line 37 with the following paragraph:

Next, pUC119-A1 and pPF260-A were double-digested with restriction enzymes PstI and BamHI to prepare DNA fragments of approximately 1.7 kbp and approximately 8.6 kbp, and then these fragments were ligated to obtain plasmid pPF260-A2. Further, pPF260-A2 was digested with restriction enzyme XbaI and then self-ligated using T4 DNA ligase to obtain plasmid pPF260-A3.

Page 42, line 1, replace the heading with the following new heading:

ABSTRACT OF THE DISCLOSURE

In the Sequence Listing:

Kindly replace the Sequence Listing of record with the attached substitute Sequence Listing.

REMARKS

Favorable consideration is respectfully requested in view of the foregoing amendments and the following remarks.

The specification has been reviewed and minor editorial changes have been effected. All of the changes are minor in nature and therefore do not require extensive discussion.
In particular, the specification headings have been amended in conformance with U.S. practice.

Support for the amendments effected on pages 31 and 32 of the specification can be found on page 31, lines 19-28, and Figure 8 of the specification.

Applicants have also submitted a revised Sequence Listing in both paper and computer readable form. Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added. Specifically, the sequences of SEQ ID Nos: 15-20 have been corrected to correspond to the sequences shown on pages 31 and 32 of the specification.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

In view of the foregoing amendments and remarks, it is respectfully submitted that the

Application is now in optimal form for examination. Such action is thus respectfully solicited.

Respectfully submitted,

Koji YANAI et al.

By: _____

Lee Cheng
Registration No. 40,949
Attorney for Applicants

LC/gtn
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
April 29, 2002